{
  "docId": "019de073-7b6a-72bb-8d98-812d56d63617",
  "docSlug": "f8b2787992eb3375620f74057447d0c9",
  "documentTitle": "Aravive | Investor Presentation Deck | 39 slides",
  "authorId": "aravive",
  "authorName": "Aravive",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 39,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "testimonial",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses qualitative feedback from healthcare providers and KOLs to validate market demand.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7b6a-72bb-8d98-812d56d63617/20",
  "deckHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617",
  "deckJsonHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617.json",
  "deckAnchorHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617#slide-20",
  "components": [
    {
      "bbox": {
        "x": 0.7,
        "y": 0.35
      },
      "kind": "quote",
      "text": "To see this level of safety with the improved efficacy is impressive - I certainly would use this product. - KOL",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2037bdf0-f21d-4748-afde-de216113b778",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "x": 0.6,
        "y": 0.7
      },
      "kind": "quote",
      "text": "Bevacizumab is only used as a palliative agent in my practice. I've had patients develop clots and bowel perforations from it, and the limited efficacy it may provide is not worth that risk. - Healthcare Provider",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "454bb8ae-46b1-4d43-809f-3b0dc9f14b27",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "x": 0.5,
        "y": 0.5
      },
      "kind": "quote",
      "text": "The all-comers data is helpful to know, but the bev-naïve data is quite transformative. - KOL",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62bed9f1-1218-4c51-ab32-274b4e431357",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "x": 0.5,
        "y": 0.2
      },
      "kind": "quote",
      "text": "Platinum resistant patients are in need of new targeted treatment options. - Healthcare Provider",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79aa2194-cf67-4bd9-9a80-b881b7d680ff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "x": 0.5,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Note: physicians' comments based on P1b data",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f0a7f2d-21ed-4f91-836f-2e2773e36416",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "x": 0.05,
        "y": 0.3
      },
      "kind": "table",
      "text": "Improved Efficacy over SOC: Favorable efficacy and a novel MOA were met with enthusiasm given ability to address unmet needs. Favorable Safety Compared to Bev Doublets: Physicians deemed the lack of additional toxicity to be impressive for a doublet regimen, particularly in comparison to bevacizumab in the U.S.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c13670ff-efde-40ed-ba2c-0b15e2bd062e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Market Research Suggests Batiraxcept Would Fill an Unmet Need and Be Adopted into the Current PROC Treatment Paradigm",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a0aa9063-0f04-4f9c-b733-1f2cb3a12e9e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}